Ultragenyx Faces a Gene-Therapy Growth Test After Two FDA Approvals and Workforce Cuts
Ultragenyx’s two FDA-approved gene therapies mark a commercial shift, but Q3 revenue of $173 million came with a $118 million net loss.
GRAIL Stock Nears 52-Week High as FDA Panel Backs Cancer Detection Test Ahead of Earnings
GRAIL shares stand near their 52-week high as an FDA panel backs its cancer test and earnings approach, setting up two potential volatility catalysts.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Compass Pathways Slides as Psychedelic Drug Race Raises Competitive Pressure
Compass Pathways faces renewed investor scrutiny as competition in the psychedelic-medicine approval race challenges fir…
United Therapeutics Removes Pfizer Royalty Overhang Ahead of Ralinepag FDA Decision
United Therapeutics paid $525 million to eliminate a Pfizer royalty obligation as once-daily oral ralinepag remains unde…
Cerus Shares Jump After Phase 3 Data Supports INTERCEPT Blood-Safety Platform
Cerus shares jumped after Phase 3 data showed INTERCEPT-specific antibodies in 2.2% of subjects versus zero in the contr…
Jazz Pharmaceuticals Raises Outlook as Record Revenue Masks Quarterly Loss
Jazz Pharmaceuticals delivered record Q3 revenue, raised its full-year outlook and posted a sizeable net loss—fueling de…
Pasithea Shares Rise After FDA Clears PAS-004 for Phase 2 NF1 Tumor Study
FDA clearance of Pasithea’s PAS-004 IND creates a regulatory catalyst as traders focus on the planned Phase 2 NF1 tumor …
BioNTech’s Q3 Update Puts Pipeline Progress and Revenue Diversification in Focus
BioNTech’s Q3 2026 update keeps attention on pipeline progress, potential catalysts and the effort to diversify beyond p…
Pfizer Raises 2026 Guidance After Strong Third-Quarter Results
Pfizer’s strong Q3 2026 results and raised full-year guidance provide a constructive signal on earnings momentum heading…
Waters’ MOBILion Acquisition Signals Continued Consolidation in Life-Sciences Tools
Waters’ planned MOBILion acquisition could broaden its analytical-instrumentation portfolio and reinforce its role in ph…
Bright Minds Biosciences Stock Plunges 52% After FDA Places Epilepsy Trial on Hold
Bright Minds Biosciences shares fell as much as 52% after the FDA placed its BMB-101 epilepsy trial on clinical hold.